3 Results for "

R1441C LRRK2

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "R1441C LRRK2" in MCE Product Catalog:

  • Targets Recommended:
Cat. No.: HY-148030
CAS No.: 3011029-58-3
Purity:  98.90%
Target:  

LRRK2 PROTACs Mitophagy

Research Areas:  

Neurological Disease

XL01126 is a blood-brain barrier-permeable, selective LRRK2 PROTAC degrader (DC50: 14 nM (G2019S LRRK2) and 32 nM (WT LRRK2)). XL01126 forms a positively cooperative ternary complex with VHL E3 ubiquitin ligase and LRRK2, mediating the polyubiquitination and proteasomal degradation of LRRK2. XL01126 induces Mitophagy. XL01126 is applicable to research related to Parkinson's disease .
loading...
    loading...
Cat. No.: HY-155150
CAS No.: 2415900-86-4
Purity:  99.41%
Target:  

PROTACs LRRK2

Research Areas:  

Neurological Disease

JH-XII-03-02 is a potent and selective LRRK2 PROTAC degrader. JH-XII-03-02 promotes ubiquitination and degradation of LRRK2. JH-XII-03-02 can be used for the research of Parkinson's disease .
loading...
    loading...
Cat. No.: HY-169900
CAS No.: 1842427-90-0
Target:  

LRRK2 Apoptosis

Research Areas:  

Neurological Disease

FX 2149 is a blood-brain barrier-permeable LRRK2 inhibitor. FX 2149 inhibits the GTP-binding activity of LRRK2, reduces the kinase activity of LRRK2, and attenuates LPS (HY-D1056)-induced upregulation of LRRK2. FX 2149 alleviates mutant LRRK2-induced neurodegeneration, microglial activation, static aggregation of mitochondria and lysosomes, reduces apoptosis, and improves mitochondrial and lysosomal motility deficits in neurites. FX 2149 can be used in research related to Parkinson's disease .
loading...
    loading...